Follicular lymphoma (FL) usually requires multiple lines of therapy and disease control remains largely insufficient with conventional chemoimmunotherapy. Several T-cell redirecting strategies recently approved in the relapsed/refractory setting have the potential to improve outcomes and change the treatment algorithm in FL. This review focuses on the role of chimeric antigen receptor T-cells and bispecific antibodies in FL, paying special attention to sequencing approaches and future directions.

中文翻译：

---

使用 T 细胞重定向策略构建滤泡性淋巴瘤的未来管理。


滤泡性淋巴瘤 （FL） 通常需要多线治疗，而传统化学免疫疗法的疾病控制在很大程度上仍然不足。最近在复发/难治性环境中批准的几种 T 细胞重定向策略有可能改善 FL 的结局并改变治疗算法。本文重点介绍嵌合抗原受体 T 细胞和双特异性抗体在 FL 中的作用，特别关注测序方法和未来方向。